• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Bio-Techne Corp (TECH)

Common Shares
Sell: $65|Buy: $88.32|Change: 0.66 (-0.79%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%),with the rest of the world accounting for the remaining 5%.

Address

614 McKinley Place N.E
Minneapolis
MN
USA
55413

Telephone

+1 646 2771266

Website

https://www.bio-techne.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Bio-Techne Corp Third Quarter Earnings Conference Call for 20252025-05-01T08:00:00
Bio-Techne Corp Third Quarter Earnings Results for 20252025-05-01T00:00:00
Bio-Techne Corp Second Quarter Earnings Conference Call for 20252025-01-31T08:00:00
Bio-Techne Corp Second Quarter Earnings Results for 20252025-01-31T00:00:00
Bio-Techne Corp First Quarter Earnings Conference Call for 20252024-10-31T08:00:00
Bio-Techne Corp First Quarter Earnings Results for 20252024-10-31T00:00:00
Bio-Techne Corp Annual General Meeting for 20242024-10-25T08:00:00
Bio-Techne Corp Annual Report for 20242024-08-23T00:00:00
Bio-Techne Corp Fourth Quarter Earnings Conference Call for 20242024-08-08T08:00:00
Bio-Techne Corp Fourth Quarter Earnings Results for 20242024-08-08T00:00:00
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024 PR Newswire2024-05-14T14:20:00
Characterization of Adeno-Associated Virus Capsids by a Novel Capillary Isoelectric Focusing Based Fractionation Method and Charge-Detection Mass Spectrometry2024-05-10T12:00:00
Next Generation Protein Characterization of CD19-CAR Signaling Cascades2024-05-09T12:00:00
A Versatile Assay for Same-Section Spatial Visualization of Small RNA, mRNA, Exon Junction, Protein and Protein-Protein Interactions2024-05-09T12:00:00
RNA/Protein Multiomics Imaging Using RNAscope™ Technologies to Understand Nonclinical Biodistribution (BD) and Persistence of Gene Therapy (GT) Products2024-05-09T12:00:00
Novel RNAscope™ Multi-omics Spatial Approach to Characterize Biodistribution and Safety of Cell and Gene Therapies2024-05-08T16:45:00
Advancements in GMP and Closed System Reagents for Immune Cell Therapy Manufacturing2024-05-08T15:45:00
Efficient T-cell Activation and Expansion for CAR-T Therapy is Dependent on a Complex Interplay of the Starting Donor Population, Activation Antibodies and Expansion Platform2024-05-08T12:00:00
Protein Analytics Strategies for Gene Therapy – from Viral Vector Characterization to Clinical Trials2024-05-08T08:30:00
Bio-Techne Corp Third Quarter Earnings Conference Call for 20242024-05-01T08:00:00
Bio-Techne Corp Third Quarter Earnings Result for 20242024-05-01T00:00:00

Previous key dates

NameKey Date
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024 PR Newswire2024-05-14T14:20:00
Characterization of Adeno-Associated Virus Capsids by a Novel Capillary Isoelectric Focusing Based Fractionation Method and Charge-Detection Mass Spectrometry2024-05-10T12:00:00
Next Generation Protein Characterization of CD19-CAR Signaling Cascades2024-05-09T12:00:00
A Versatile Assay for Same-Section Spatial Visualization of Small RNA, mRNA, Exon Junction, Protein and Protein-Protein Interactions2024-05-09T12:00:00
RNA/Protein Multiomics Imaging Using RNAscope™ Technologies to Understand Nonclinical Biodistribution (BD) and Persistence of Gene Therapy (GT) Products2024-05-09T12:00:00
Novel RNAscope™ Multi-omics Spatial Approach to Characterize Biodistribution and Safety of Cell and Gene Therapies2024-05-08T16:45:00
Advancements in GMP and Closed System Reagents for Immune Cell Therapy Manufacturing2024-05-08T15:45:00
Efficient T-cell Activation and Expansion for CAR-T Therapy is Dependent on a Complex Interplay of the Starting Donor Population, Activation Antibodies and Expansion Platform2024-05-08T12:00:00
Protein Analytics Strategies for Gene Therapy – from Viral Vector Characterization to Clinical Trials2024-05-08T08:30:00
Bio-Techne Corp Third Quarter Earnings Conference Call for 20242024-05-01T08:00:00
Bio-Techne Corp Third Quarter Earnings Result for 20242024-05-01T00:00:00
BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM2024-03-19T08:30:00
THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE2024-03-13T08:30:00
Bio-Techne Corp Second Quarter Earnings Conference Call for 20242024-02-01T08:00:00
Bio-Techne Corp Second Quarter Earnings Result for 20242024-02-01T00:00:00
Bio-Techne Corp First Quarter Earnings Conference Call for 20242023-10-31T08:00:00
Bio-Techne Corp First Quarter Earnings Result for 20242023-10-31T00:00:00
Bio-Techne Corp Annual General Meeting for 20232023-10-26T08:00:00
Bio-Techne Corp Annual Report for 20232023-08-23T00:00:00
Bio-Techne Corp Fourth Quarter Earnings Conference Call for 20232023-08-08T08:00:00
Bio-Techne Corp Fourth Quarter Earnings Result for 20232023-08-08T00:00:00
Bio-Techne Corp Third Quarter Earnings Conference Call for 20232023-05-03T08:00:00
Bio-Techne Corp Third Quarter Earnings Result for 20232023-05-03T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.